Drag Pharma

Glicefar®

Central Muscle Relaxant

Adjuvant for the induction of anesthesia in horses.
It can be used as an inducing agent in combination with barbiturates to smooth the induction and recovery stage of the latter. It can also be used in combination with other agents such as Xylazine and Ketamine, for the maintenance of anesthesia and thus decrease the concentration of inhalational anesthesia.
Its use is recommended only in adult horses.

Data Sheet

Solution for injection.

Central muscle relaxant.

Each mL of product contains:
Guaifenesina………………………… 100 mg
Excipients c.s.p……………………… 1 mL

Adjuvant for the induction of anesthesia in horses.
It can be used as an inducing agent in combination with barbiturates to smooth the induction and recovery stage of the latter. It can also be used in combination with other agents such as Xylazine and Ketamine, for the maintenance of anesthesia and thus decrease the concentration of inhalational anesthesia.
Its use is recommended only in adult horses.

Horses.

  • For use in combination with barbiturates, add the dose of barbiturates (e.g., thiopental) to the glycepar® solution prior to administration and proceed with the infusion, or administer as a bolus immediately after administration of glyceph®
  • For use in combination with Xylazine and/or Ketamine, Xylazine is administered 2 to 5 minutes before, then Glycepfar® is administered at the recommended dose, and then Ketamine is administered, once signs of ataxia produced by Glycephar® are observed

Intravenous administration only.

  • Recommended dose: 100 – 110 mg/kg body weight.
  • Recommended practical dose: 1 mL/kg body weight.

Do not use on horses whose meat is intended for human consumption.

Do not administer to pregnant or lactating females.

Symptoms of apneic breathing, nystagmus, hypotension, and muscle stiffness are associated with toxic levels of the drug. There is no specific antidote.
Up to one liter of the product can be administered without any toxic effects being observed in the individual.

Extravascular injection should be avoided as it can cause tissue irritation.
It is recommended to monitor the patient’s heart and respiratory rate when Guaifenesin is administered.

  • Guaifenesin is an irritant to the skin and mucous membranes, so direct contact with people should be avoided, as well as accidental ingestion. For this, the use of disposable gloves is recommended when handling the product.
  • Wash your hands after using the product.
  • Guaifenesin may cause hypersensitivity reactions.

Keep out of reach of children and pets.

Keep in a cool, dry place, between 15 and 30°C and away from light.

Sale by prescription to the Veterinary Doctor.

VETERINARY USE

Chile: Reg. SAG N° 2039
Costa Rica: Reg. No. MV-6176
Peru: Reg. SENASA F.A0.01.I.0004
Imported and distributed by Durand SAC Representations.
Av. Manuel Olguín N° 501 Oficina N° 604 Santiago de Surco Lima.

Serum bottle with 500 mL

Laboratorio Drag Pharma Chile Invetec S.A.
Lautaro N° 300. Quilicura. Santiago. Chile.

*Important:

You have accessed information referring to pharmaceutical products authorized for sale under a medical prescription. In accordance with Chilean legislation, the promotion and advertising of these products is restricted to professionals who prescribe and dispense them. The information contained on this page is specialized technical and scientific information.